NEWRON PHARMACEUTICALS SPA
- Country
- 🇮🇹Italy
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.newron.com
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 138
- Registration Number
- NCT04461119
- Locations
- 🇮🇳
Sri Ramachandra Medical College, Department of Psychiatry, Chennai, Tamil Nadu, India
🇮🇳St. John's Medical College Hospital, Koramangala, Karnataka, India
🇮🇳Help Hospitals Clinical Research Department, Vijayawada, Andhra Pradesh, India
An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects
- Conditions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 6
- Registration Number
- NCT03446274
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, NG, United Kingdom
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
- Conditions
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 129
- Registration Number
- NCT02790034
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇮🇹U.O. Neuropsichiatria Infantile, Milano, Italy
🇦🇺South Metropolitan Health Service Fiona Stanley Hospital, Murdoch, Western Australia, Australia
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 90
- Registration Number
- NCT02624167
- Locations
- 🇺🇸
Collaborative Neuroscience Network., Garden Grove, California, United States
🇮🇳KHM Hospital, Chennai, Tamil Nadu, India
🇮🇳Tirthalli National Institute of Mental Health and Neurosciences, Bangalore, India
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 54
- Registration Number
- NCT01955564
- Locations
- 🇺🇸
Collaborative Neuroscience Network-Clinical Pharmacology Unit, Long Beach, California, United States
Safinamide Renal Impairment Trial
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 24
- Registration Number
- NCT01374113
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 544
- Registration Number
- NCT01286935
A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging
- First Posted Date
- 2010-12-22
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 5
- Registration Number
- NCT01264861
- Locations
- 🇺🇸
Molecular Neuroimaging, LLC, New Haven, Connecticut, United States
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2013-03-29
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 103
- Registration Number
- NCT01211587
- Locations
- 🇪🇸
Hosptial General Univ Gregorio Maranon, Madrid, Spain
🇺🇸The Parkinson's Institute, Sunnyvale, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2010-08-24
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 669
- Registration Number
- NCT01187966